![Logo](/assets/logo-d3f1fdf60522f0983e71f9fcc720cb7da5b55c0b748ed5bded3d2fbf81387bf0.png)
PMC:7696151 / 13787-14115
Annnotations
LitCovid-PubTator
Id | Subject | Object | Predicate | Lexical cue | tao:has_database_id |
---|---|---|---|---|---|
409 | 93-101 | Species | denotes | patients | Tax:9606 |
410 | 220-228 | Species | denotes | patients | Tax:9606 |
424 | 0-3 | Chemical | denotes | HCQ | MESH:D006886 |
425 | 5-16 | Chemical | denotes | hydroxyurea | MESH:D006918 |
426 | 22-32 | Chemical | denotes | didanosine | MESH:D016049 |
427 | 146-149 | Chemical | denotes | HCQ | MESH:D006886 |
428 | 158-169 | Chemical | denotes | hydroxyurea | MESH:D006918 |
429 | 186-196 | Chemical | denotes | didanosine | MESH:D016049 |
439 | 74-86 | Disease | denotes | HIV-infected | MESH:D015658 |
LitCovid-sentences
Id | Subject | Object | Predicate | Lexical cue |
---|---|---|---|---|
T109 | 117-209 | Sentence | denotes | All subjects received 200 mg HCQ, 500 mg hydroxyurea, and 125–200 mg didanosine twice daily. |
T110 | 210-296 | Sentence | denotes | Of the 17 patients who started treatment, 14 remained until the end of the 144th week. |